赛妥珠单抗-话题@MedSci

#赛妥珠单抗#

8篇内容 | 1118人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1264106, encodeId=b5f1126410684, content=<a href='/topic/show?id=dd729261097' target=_blank style='color:#2F92EE;'>#赛妥珠单抗#</a>, objectTitle=降低死亡风险49%! 吉利德靶向TROP-2赛妥珠单抗Trodelvy成功上市, objectType=article, longId=209875, objectId=65ca2098e566, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65ca2098e566, replyNumber=0, likeNumber=38, createdTime=2021-04-14, rootId=0, userName=wfang545, userId=cfa576, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65ca2098e566, moduleTitle=降低死亡风险49%! 吉利德靶向TROP-2赛妥珠单抗Trodelvy成功上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65ca2098e566)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264105, encodeId=1b6512641057b, content=<a href='/topic/show?id=dd729261097' target=_blank style='color:#2F92EE;'>#赛妥珠单抗#</a>, objectTitle=Clin Cancer Res：纳武单抗+伊匹单抗+英夫利昔单抗/赛妥珠单抗治疗黑色素瘤, objectType=article, longId=205435, objectId=735520543511, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=735520543511, replyNumber=0, likeNumber=45, createdTime=2021-01-08, rootId=0, userName=wfang545, userId=cfa576, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=735520543511, moduleTitle=Clin Cancer Res：纳武单抗+伊匹单抗+英夫利昔单抗/赛妥珠单抗治疗黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=735520543511)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264104, encodeId=cea6126410466, content=<a href='/topic/show?id=dd729261097' target=_blank style='color:#2F92EE;'>#赛妥珠单抗#</a>, objectTitle=UCB的抗TNF单抗赛妥珠单抗在加拿大获准用于治疗非放射性轴突性脊柱关节炎, objectType=article, longId=186376, objectId=0af51863e634, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0af51863e634, replyNumber=0, likeNumber=26, createdTime=2020-01-18, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0af51863e634, moduleTitle=UCB的抗TNF单抗赛妥珠单抗在加拿大获准用于治疗非放射性轴突性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0af51863e634)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264103, encodeId=729212641031f, content=<a href='/topic/show?id=dd729261097' target=_blank style='color:#2F92EE;'>#赛妥珠单抗#</a>, objectTitle=Clin Exp Rheumatol：赛妥珠单抗治疗类风湿性关节炎的疗效和安全性, objectType=article, longId=165130, objectId=fbbc16513063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbbc16513063, replyNumber=0, likeNumber=41, createdTime=2019-04-30, rootId=0, userName=wfang545, userId=cfa576, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbbc16513063, moduleTitle=Clin Exp Rheumatol：赛妥珠单抗治疗类风湿性关节炎的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbbc16513063)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264102, encodeId=2b6c12641021c, content=<a href='/topic/show?id=dd729261097' target=_blank style='color:#2F92EE;'>#赛妥珠单抗#</a>, objectTitle=FDA批准将赛妥珠单抗用于治疗非放射性轴性脊柱关节炎（nr-axSpA）, objectType=article, longId=163432, objectId=dd7516343269, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd7516343269, replyNumber=0, likeNumber=39, createdTime=2019-04-03, rootId=0, userName=wfang545, userId=cfa576, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd7516343269, moduleTitle=FDA批准将赛妥珠单抗用于治疗非放射性轴性脊柱关节炎（nr-axSpA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd7516343269)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264101, encodeId=ebba1264101c8, content=<a href='/topic/show?id=dd729261097' target=_blank style='color:#2F92EE;'>#赛妥珠单抗#</a>, objectTitle=Arthritis Rheumatol：早期类风湿关节炎治疗1年后赛妥珠单抗是维持、减量还是停药？, objectType=article, longId=105180, objectId=883c10518016, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=883c10518016, replyNumber=0, likeNumber=34, createdTime=2017-07-12, rootId=0, userName=wfang545, userId=cfa576, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=883c10518016, moduleTitle=Arthritis Rheumatol：早期类风湿关节炎治疗1年后赛妥珠单抗是维持、减量还是停药？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=883c10518016)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264100, encodeId=592e126410045, content=<a href='/topic/show?id=dd729261097' target=_blank style='color:#2F92EE;'>#赛妥珠单抗#</a>, objectTitle=EULAR 2016：赛妥珠单抗可快速缓解中轴性脊柱关节炎患者的症状且效果可长达4年, objectType=article, longId=71882, objectId=8fe0e188265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fe0e188265, replyNumber=0, likeNumber=46, createdTime=2016-07-01, rootId=0, userName=wfang545, userId=cfa576, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fe0e188265, moduleTitle=EULAR 2016：赛妥珠单抗可快速缓解中轴性脊柱关节炎患者的症状且效果可长达4年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fe0e188265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264099, encodeId=dc3412640993b, content=<a href='/topic/show?id=dd729261097' target=_blank style='color:#2F92EE;'>#赛妥珠单抗#</a>, objectTitle=优时比旗下赛妥珠单抗获FDA批准用于成人银屑病性关节炎, objectType=article, longId=25239, objectId=500625239d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=500625239d4, replyNumber=0, likeNumber=36, createdTime=2013-10-11, rootId=0, userName=wfang545, userId=cfa576, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=500625239d4, moduleTitle=优时比旗下赛妥珠单抗获FDA批准用于成人银屑病性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=500625239d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

赛妥珠单抗

2020-05-29

wfang545 (审核中...)

前往app查看评论内容

#赛妥珠单抗#

降低死亡风险49%! 吉利德靶向TROP-2赛妥珠单抗Trodelvy成功上市

2021-04-14

wfang545 (审核中...)

前往app查看评论内容

#赛妥珠单抗#

Clin Cancer Res：纳武单抗+伊匹单抗+英夫利昔单抗/赛妥珠单抗治疗黑色素瘤

2021-01-08

智慧医人 (审核中...)

前往app查看评论内容

#赛妥珠单抗#

UCB的抗TNF单抗赛妥珠单抗在加拿大获准用于治疗非放射性轴突性脊柱关节炎

2020-01-18

wfang545 (审核中...)

前往app查看评论内容

#赛妥珠单抗#

Clin Exp Rheumatol：赛妥珠单抗治疗类风湿性关节炎的疗效和安全性

2019-04-30

wfang545 (审核中...)

前往app查看评论内容

#赛妥珠单抗#

FDA批准将赛妥珠单抗用于治疗非放射性轴性脊柱关节炎（nr-axSpA）

2019-04-03

wfang545 (审核中...)

前往app查看评论内容

#赛妥珠单抗#

Arthritis Rheumatol：早期类风湿关节炎治疗1年后赛妥珠单抗是维持、减量还是停药？

2017-07-12

wfang545 (审核中...)

前往app查看评论内容

#赛妥珠单抗#

EULAR 2016：赛妥珠单抗可快速缓解中轴性脊柱关节炎患者的症状且效果可长达4年

2016-07-01

wfang545 (审核中...)

前往app查看评论内容

#赛妥珠单抗#

优时比旗下赛妥珠单抗获FDA批准用于成人银屑病性关节炎

2013-10-11

科室
- - 订阅+
  - 更多科室
工具
服务